Roche to Present its Oncology Portfolio at the ESMO Virtual Congress 2020
Shots:
- Roche highlights data from three P-III studies across the Tecentriq (atezolizumab) TNBC programme- CNS efficacy data from integrated analyses of the pivotal Rozlytrek (entrectinib) clinical development program- and the data from the registrational P-I/II ARROW trial assessing Gavreto (pralsetinib) for RET-mutant MTC patients
- Data from the P-III IPATential150 study in mCRPC patients and whose tumors had PTEN loss will also be presented
- Roche will be hosting a live roundtable discussion focusing on COVID-19 and the impact it may have on the outcomes for cancer patients. The discussion will focus on potential solutions and the lessons have been learned from the pandemic so far
Ref: Roche | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com